The effect of novel antipsychotics on cognitive function

Psychiatric Annals

Volumn 29, Issue 11, 1999, Pages 643-646

  Berman, Ileana ^a   Klegon, David ^b   Fiedosewicz, Hannah ^b   Chang, Howard ^b  

^a Taunton State Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033463522     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19991101-10     Document Type: Article

References (28)

1. Strahan GW. Prevalence of selected mental disorders in nursing and related care homes. In: Manderscheid RW, Sonnenschein MA, eds. Mental Health, United States 1990. Washington, DC: U.S. Government Printing Office; 1990:227-240. National Institute of Mental Health DHHS Publication No. (ADM) 90-1708.
2. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239-246.
3. Stip E, Lussier T. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 1996; 2(suppl 2):535-540.
4. Berman I, Viegner B, Merson A, Alan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res. 1997;25:1-10.
5. Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. 1991;5:123-134.
6. Borison RL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand. 1996;94:5-11.
7. Mortimer AM. Cognitive function in schizophrenia: do neuroleptics make a difference? Pharmacol Biochem Behav. 1997;56:789-795.
8. Collaborative Working Group on Clinical Trial Evaluations. Evaluating the effects of antipsychotics on cognition in schizophrenia. J Clin Psychiatry. 1998; 59(suppl 12):35-40.
9. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55(suppl B):47-52.
10. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry. 1998;59:184-188.
11. Lindenmayer J-P, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry. 1998;59:521-527.
12. Green MF, Marshall BD, Wirshing MD, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154:799-804.
13. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996;6(suppl 2):S13-S20.
14. Berman I, Merson A, Rachov-Pavlov J, Allan E, Davidson M, Losonczy MF. Risperidone in elderly schizophrenic patients: an open-label trial pilot study. Am J Geriatr Psychiatry. 1996;4:173-179.
15. Berman I, Merson A, Allan E, Sison C, Alexis C, Losonczy MF. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol. Presented at the annual meeting of the New Clinical Drug Evaluation Unit; Orlando, Florida; May 1995.
16. Pappas D, Leventhal N, Langlois J, Osser D, Chang H, Berman I. Effect of risperidone on cognitive function in schizophrenic patients: an open label study. Presented at the annual meeting of the American Psychiatric Association; San Diego, California; May 1997.
17. Kay SR, Fizbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
18. Kay SR. Positive and Negative Syndromes in Schizophrenia: Assessment and Research. New York: Brunner/Mazel; 1991.
19. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res. 1975;12:189-198.
20. Berman I, Pappas D, Bayog R, Wu C, Osser D, Karshaw A. Cognitive effect of olanzapine. Presented at the annual meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
21. Berman I, Pappas D, Bayog R, Wu C, Osser D. Gender and cognitive response to neuroleptics. Presented at the annual meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 30-June 4, 1998.
22. Davidson M, Harvey PD, Powchik P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995;152:197-207.
23. Walker E, Harvey P. Positive and negative symptoms in schizophrenia: attentional performance correlates. Psychopathology. 1986;19:294-302.
24. Berman I, Pappas D, Leventhal N, et al. The relationship between changes in schizophrenic symptoms and cognitive deficits during treatment with an atypical neuroleptic. Presented at the annual meeting of the American Psychiatric Association; San Diego, California; May 1997.
25. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet. 1992; 340:1136-1139.
26. Berman I, Pappas D, Leventhal N, Osser D, Sigadel R, Patel C. Ginkgo biloba extract in schizophrenic patients. Presented at the annual meeting of the New Clinical Drug Evaluation Unit; Boca Raton, Florida; June 1997.
27. Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry. 1996;57(suppl 11):31-39.
28. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol. 1998;18(suppl 1):S12-S19.